Related Experiment Videos

TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications

Rhianna K Lenham1, Fatema Elgammal2, Scott V Harding2

  • 1Department of Human Biosciences, Memorial University of Newfoundland, St. John's, Canada. rlenham@mun.ca.

Handbook of Experimental Pharmacology
|July 10, 2026
PubMed

Insights

Trace amine-associated receptor 1 (TAAR1) shows promise for metabolic disorders. TAAR1 activation may improve insulin secretion and offer a safer alternative to existing treatments for type 2 diabetes mellitus.

Area of Science:

  • Endocrinology and Metabolism
  • Neuropharmacology

Background:

  • Metabolic syndrome impacts over 30% globally, characterized by insulin resistance, obesity, and dyslipidemia, increasing risks for type 2 diabetes mellitus (T2DM).
  • Current antihyperglycemic treatments often lose efficacy over time, necessitating novel therapeutic agents with diverse mechanisms.

Purpose of the Study:

  • To review the emerging role of trace amine-associated receptor 1 (TAAR1) in regulating metabolic function.
  • To explore TAAR1's potential as a therapeutic target for metabolic diseases, considering both physiological and neurobehavioral aspects.

Main Methods:

  • Review of preclinical and clinical evidence on TAAR1 agonism in metabolic regulation.
  • Comparative analysis of TAAR1 mechanisms with existing incretin mimetic therapies like semaglutide (a GLP-1 receptor agonist).

Main Results:

  • TAAR1 activation enhances glucose-stimulated insulin secretion.
  • TAAR1 regulates dopaminergic pathways involved in addiction and reward processes.
  • TAAR1 exhibits mechanistic overlap with incretin mimetics but may offer a superior metabolic safety profile.

Conclusions:

  • Trace amine-associated receptor 1 (TAAR1) is a promising target for metabolic diseases.
  • TAAR1 activation presents potential advantages over current therapies, including improved safety.
  • Targeting TAAR1 could address both physiological and neurobehavioral facets of metabolic dysfunction.
Keywords:
Glucagon-like peptide-1 (GLP-1)Glucose-stimulated insulin secretionMetabolic syndromeSemaglutideTrace amine-associated receptor 1 (TAAR1)Type 2 diabetes mellitusUlotaront

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...